Connect with us

Health

Nearly 3 million People Access Hepatitis C Cure—WHO

Published

on

By Dipo Olowookere

The World Health Organisation (WHO) has revealed that a record 3 million people were able to obtain treatment for hepatitis C over the past two years, and 2.8 million more people embarked on lifelong treatment for hepatitis B in 2016.

This information is coming as stakeholders in the health sector across the globe gather in Brazil for the World Hepatitis Summit.

WHO stated that lately, there has been increasing global momentum in the response to viral hepatitis.

“We have seen a nearly 5-fold increase in the number of countries developing national plans to eliminate life-threatening viral hepatitis over the last 5 years,” says Dr Gottfried Hirnschall, Director of WHO’s Department of HIV and Global Hepatitis Programme. “These results bring hope that the elimination of hepatitis can and will become a reality.”

Hosted by the Government of Brazil, the World Hepatitis Summit 2017 is being co-organized by the World Health Organization and the World Hepatitis Alliance. The Summit aims to encourage more countries to take decisive action to tackle hepatitis, which still causes more than 1.3 million deaths every year and affects more than 325 million people.

“We cannot lose sight of the fact that last year 194 governments committed to eliminating viral hepatitis by 2030. For sure we are still a long way from this goal but that doesn’t mean it’s some unattainable dream. It’s eminently achievable. It just requires immediate action,” says Charles Gore, President of World Hepatitis Alliance. “The World Hepatitis Summit 2017 is all about how to turn WHO’s global strategy into concrete actions and inspire people to leave with a ‘can do’ attitude.”

“Brazil is honoured to host the World Hepatitis Summit 2017 – and welcomes this extraordinary team of experts, researchers, managers and civil society representatives to discuss the global health problem posed by viral hepatitis,” says Dr Adele Schwartz Benzaken, Director of the Brazilian Ministry of Health’s Department of Surveillance, Prevention and Control of STIs, HIV/AIDS and Viral Hepatitis.” Brazil is committed to taking recent advances in its response to hepatitis forward – on the road to elimination.”

Progress in treatment and cure

Many countries are demonstrating strong political leadership, facilitating dramatic price reductions in hepatitis medicines, including through the use of generic medicines—which allow better access for more people within a short time.

In 2016, 1.76 million people were newly treated for hepatitis C, a significant increase on the 1.1 million people who were treated in 2015. The 2.8 million additional people starting lifelong treatment for hepatitis B in 2016 was a marked increase from the 1.7 million people starting it in 2015. But these milestones represent only initial steps – access to treatment must be increased globally if the 80% treatment target is to be reached by 2030.

However, funding remains a major constraint: most countries lack adequate financial resources to fund key hepatitis services.

Diagnosis challenge

To achieve rapid scale-up of treatment, countries need urgently to increase uptake of testing and diagnosis for hepatitis B and C. As of 2015, an estimated 1 in 10 people living with hepatitis B, and 1 in 5 people living with hepatitis C, were aware of their infection. Countries need to improve policies, and programmes to increase awareness and subsequent diagnosis.

Prevention gaps

Countries need to provide a full range of hepatitis prevention services that are accessible to different population groups, particularly those at greater risk.

Largely due to increases in the uptake of hepatitis B vaccine, hepatitis B infection rates in children under 5 fell to 1.3% in 2015, from 4.7% in the pre-vaccine era.

However, the delivery of other prevention services, such as birth-dose vaccination for hepatitis B, harm reduction services for people who inject drugs, and infection control in many health services, remains low. This has led to continuing rates of new infections, including 1.75 million new hepatitis C cases every year.

Need for innovation

Innovation in many aspects of the hepatitis response must continue. New tools required include a functional cure for hepatitis B infection and the development of more effective point-of-care diagnostic tools for both hepatitis B and C.

“We cannot meet the ambitious hepatitis elimination targets without innovation in prevention interventions and approaches, and implementing them to scale,” said Dr Ren Minghui, Assistant Director-General for Communicable Diseases, WHO. “The great successes of hepatitis B vaccination programmes in many countries need to be replicated and sustained globally in the context of moving forward to universal health coverage.“

Implementation of elimination strategy

The World Hepatitis Summit 2017 will be attended by over 900 delegates from more than 100 countries, including Ministers of Health, national programme managers, and representatives from organizations of people affected by viral hepatitis. The Summit will review progress and renew commitments by global partners to achieve the elimination of viral hepatitis by 2030 – a target reflected in WHO’s elimination strategy and the UN Sustainable Development Goals.

Dipo Olowookere is a journalist based in Nigeria that has passion for reporting business news stories. At his leisure time, he watches football and supports 3SC of Ibadan. Mr Olowookere can be reached via [email protected]

1 Comment

1 Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Burundi Introduces Malaria Vaccine Into Routine Immunization Programme

Published

on

Malaria Deaths

By Modupe Gbadeyanka

The government of Burundi has taken a critical step towards reducing malaria cases and saving thousands of children’s lives with the introduction of the malaria vaccine into its routine immunization programme.

This followed the arrival of 544,000 doses of malaria vaccines in Burundi in January and the approval of the RTS,S malaria vaccine by ABREMA (Autorité Burundaise de Régulation des Médicaments à usage humain et des Aliments).

The inclusion of the vaccine was made possible with the collaborations of the Ministry of Health, Gavi, the Vaccine Alliance (Gavi), UNICEF, the World Health Organization (WHO), and Dalberg.

At a ceremony on Monday to announce this development, the First Lady of Burundi, Mrs Angeline Ndayishimiye, commended the organisations for supporting her husband’s government to fight malaria in the country.

Malaria remains a major public health concern in Burundi and one of the country’s top health priorities. Malaria is endemic, with two annual peaks (April-May and June) resulting in high transmission levels in some districts.

The latest data from the National Health Information System (SNIS) showed that malaria remains one of the leading causes of morbidity and mortality, with an incidence of 399.1 per 1,000 inhabitants in 2023.

Data analysis revealed that malaria accounted for 20.9 per cent of consultations in 2023 and 59.4 per cent of hospital deaths in 2021.

In Burundi, children under the age of five are the population category most vulnerable to malaria. Of the 4,857,556 malaria cases reported in 2023, children under five accounted for 2,235,481 cases, representing 46 per cent of malaria morbidity.

For this reason, as a key partner, UNICEF is committed to ensuring that every child, especially the most vulnerable, has access to this critical vaccine, alongside other essential health services, to give them a healthier start in life.

“Today marks a significant milestone as we introduce the malaria vaccine in Burundi. This initiative reflects our strong and unwavering commitment to malaria control by combining high-impact strategic interventions and our collective determination to protect our children’s lives.

“By focusing on reducing malaria mortality in children under five, we are taking a critical step towards ensuring a healthier and brighter future for the next generation. This vaccine introduction also brings us closer to a future where no child is lost to this preventable disease. We are paving the way for a malaria-free Burundi,” said Dr Lydwine Baradahana, Minister of Public Health and AIDS Prevention.

“Today, Burundi joins the list of 17 other countries on the African continent to have introduced malaria vaccine into routine immunization with Gavi support.

“Given the devastating impact of malaria, this is a development that will save thousands of young lives, offer relief to families and lessen the burden currently placed on the country’s health system,” the Senior Country Manager for Burundi at Gavi, Mario Jimenez, stated.

UNICEF Representative in Burundi, France Bégin, said, “Every child has the right to grow up healthy and protected from preventable diseases like malaria. The introduction of the malaria vaccine is a historic step, bringing new hope to families in Burundi.”

WHO representative in Burundi, Dr Xavier Crespin, remarked that, “Malaria is the leading cause of morbidity and mortality in Burundi, especially among children.

“With the measures already taken by the government such as Sulfadoxine-Pyrimethamine chemoprevention, the distribution of impregnated mosquito nets and indoor spraying, and now the introduction of malaria vaccination in children aged 6 to 18 months as recommended by the WHO,

Continue Reading

Health

Oyo Enrols 10,000 Primary School Pupils for Healthcare Insurance Scheme

Published

on

Oyo primary school pupils insurance

By Modupe Gbadeyanka

About 10,000 primary school pupils have been enrolled by the Oyo State government for its healthcare insurance programme as part of efforts towards ensuring the children are of sound minds.

The beneficiaries were chosen from 90 schools across 18 local government areas of the state, and were presented their insurance scheme ID cards on Thursday at the Ibadan Civic Centre, Idi-ape, Ibadan, by the Deputy Governor, Mr Bayo Lawal.

He applauded the partnership and collaboration between the Oyo State Health Insurance Agency (OYSHIA) and the Oyo State Universal Basic Education Board (OYOSUBEB) in providing healthcare opportunities to public school children in the state.

“This scheme will ensure that our children have sound minds, while they learn in conducive environments.

“This event is a collective effort in securing a brighter future of Oyo State pupils,” the deputy governor said.

Mr Lawal also charged OYSHIA to double its efforts in extending the scheme to every school in the State, urging parents and guardians to key into the scheme.

In her goodwill message, the Chief of UNICEF in the Lagos Field Office, Ms Celine Lafoucriere, noted that the launch of the Oyo State Public Primary School Pupils Health Insurance Scheme would give access to affordable, quality healthcare; a fundamental right for every child.

“This initiative reinforces our collective commitment to universal health coverage, ensuring that no child faces financial obstacles to accessing healthcare.

“Universal health coverage is more than a healthcare goal—it’s a social and economic necessity. When children have access to healthcare, they can focus on education, grow into productive adults, break the cycle of poverty, and contribute to the success of Oyo State and Nigeria.

“This scheme exemplifies this by focusing on public primary school children, especially in hard-to-reach areas. With 90 schools already enrolled across 18 LGAs, our goal is to ensure all 33 LGAs in Oyo state are covered, leaving no child behind.

“UNICEF remains steadfast in supporting the government and communities toward universal health coverage,” she stated.

On her part, the Commissioner for Health, Dr Oluwaserimi Ajetunmobi, applauded OYSHIA and OYOSUBEB for their commitment towards healthy basic school pupils, assuring them of her Ministry’s unparalleled commitment to the scheme.

Also speaking, the Chairman of OYOSUBEB, Mr Nureni Aderemi Adeniran, applauded OYSHIA, pledging the board’s commitment to the smooth take-off and sustainability of the scheme.

“At OYOSUBEB, we operate on the principle of taking care of the pupils under our care as though they are ours,” he said, adding that the scheme would enable the beneficiaries to receive quality healthcare without paying exorbitantly to access it.

Earlier, the Executive Secretary of OYSHIA, Dr Olusola Akande, said the new door being opened today, is focusing on providing access to healthcare for 10,000 public primary school pupils in the first instance, noting that the agency will also commence an enrolment of additional 5,500 pupils into the scheme from next week.

He praised UNICEF, through whose support the agency has been able to improve on its awareness campaign and increased the communities under the Community Based Health Insurance scheme by 100 per cent.

He equally stressed the unparalleled commitment of SUBEB chairman to the scheme, stating, “His open door policy and unrestricted access ensured we were able to keep to our timeline.”

Continue Reading

Health

naturalX Secures €100m to Drive Consumer Health in Europe

Published

on

naturalX

By Adedapo Adesanya

A venture capital fund focused on consumer health startups that are reshaping the future of healthcare, naturalX Health Ventures has announced a €100 million fund to accelerate this revolution in Europe.

This makes the fund the first specialized fund focused exclusively on the intersection of consumer and health in the European market.

The fund will focus primarily on Series-A investments while remaining flexible to participate in late Seed and Series-B rounds. Typical first investments range from €3-5 million, with up to €10 million available per company.

To companies, naturalX can act as either lead investor or co-investor, targeting consumer health startups across Europe with selected investments in North America.

naturalX was founded by Mr Marvin Amberg, a German serial entrepreneur with experience launching consumer and health startups, in cooperation with Schwabe Group, a global leader in plant-based pharmaceuticals. The fund defines consumer health as the intersection of wellness and medicine, where science-backed products and services put the consumer in focus.

During its 18-month ramp-up phase, naturalX has already made several investments, including mybacs, Flow Neuroscience, Kyan Health, and Meela, while also investing in healthcare-focused VC funds to build a strong ecosystem around their thesis.

Speaking on the development, the founder of the firm, Mr Marvin Amberh “I am very excited to double down on our thesis with the official launch of naturalX. The consumer health space has been overlooked by investors.”

“We see an inflection point in Europe now, as consumers are finally taking more charge of their own health. Startups in the space need a partner with a shared vision,” he added.

The fund’s launch comes at a pivotal moment in consumer health after the COVID-19 pandemic accelerated consumers focus on proactive health management, further boosted by easier access to data through technology, including AI.

naturalX targets solutions across proactive health, including sleep, gut health, prevention, and longevity. The fund also places special emphasis on mental health, recognizing the growing need for consumer-centric therapeutic solutions in this underserved area.

The investment strategy bridges Schwabe Group’s deep pharmaceutical expertise with modern digital health innovation.

“We analysed the US health market and in many successful startups, the consumer is already at the centre. Our thesis is that this is just the beginning, and the European market will develop in a similar pattern. While we start to see some examples of consumer-focused healthcare companies in Europe reaching meaningful scale and significant funding, such as Oura or Neko Health, we think this market deserves more attention,” added Mr Amberg.

“naturalX led our Series-A round and has been an exceptional partner, bringing not only capital but also invaluable knowledge of the nutritional supplement and broader consumer health market. Their pragmatic, fast decision-making allows us to focus on growing our business,” said Mr Carl-Philipp von Polheim, Founder of mybacs, a leading DTC probiotic subscription startup.

“At Kyan Health, we are dedicated to proactive mental health management—empowering individuals before issues escalate. naturalX shares this vision, recognizing that prevention is key to lasting impact. Their deep expertise and strategic approach make them an ideal partner in driving meaningful change for millions,” said Mr Vlad Gheorghiu, Founder of Kyan Health, a leading mental health platform for employees.

Continue Reading

Trending